Company to Attend and Present at Psychedelic Therapeutics and Drug Development Conference in New Orleans, LA, February 26-27, 2026

Five Discovery announces its launch as a biotechnology company developing small-molecule therapeutics to repair dysfunctional brain circuits in neurodegenerative disease and brain injury. The company will introduce itself at the Psychedelic Therapeutics and Drug Development Conference in New Orleans, Louisiana, on February 26–27, 2026, where Chief Executive Officer Dr. Manesh Girn will present on February 26 at 3:30 p.m. a talk titled “Beyond Mood Disorders: Reframing Non-Hallucinogenic Psychedelics as Neuroregenerative Therapeutics.

Five Discovery is advancing Regenerative Neurology, an emerging therapeutic discipline focused on restoring and stabilizing dysfunctional neural circuits rather than solely managing symptoms. Its approach leverages non-hallucinogenic neuroplastogens inspired by the neurobiological mechanisms of the psychedelic molecule, 5-MeO-DMT. These small molecules are designed to preserve the validated neuroplastic and anti-inflammatory effects associated with serotonergic psychedelics while eliminating hallucinogenic activity, enabling scalable clinical development.

The company’s lead program targets Levodopa-Induced Dyskinesia (LID), a debilitating complication of long-term levodopa therapy in Parkinson’s disease. LID represents a significant unmet clinical need and a strategically focused regulatory entry point, with eligibility for orphan-drug designation, FDA-validated endpoints, and efficient trials. Clinical validation in LID will establish a foundation for future development in broader Parkinson’s Disease and additional CNS disorders.

“Neurodegenerative disorders are fundamentally disorders of circuit dysfunction,” said Dr. Manesh Girn, Co-Founder and Chief Executive Officer of Five Discovery. “Our objective is to translate the well-characterized plasticity biology of rapid-acting serotonergic therapeutics into small-molecule medicines that stabilize and restore dysfunctional neural circuits, without the hallucinogenic effects that limit psychedelic therapies.”

Five Discovery emerged from the Kaivalya Ventures ecosystem, which established a global platform spanning clinical education, therapeutic training, and applied research in the 5-MeO-DMT field. Building on the world’s largest real-world dataset of 5-MeO-DMT human observations, Five Discovery has bridged emerging clinical insights into a structured and regulator-ready drug development roadmap.

About Five Discovery

Five Discovery is a regenerative neurology biotechnology company developing non-hallucinogenic neuroplastogens inspired by 5-MeO-DMT biology. The company’s small-molecule portfolio is designed to restore and stabilize dysfunctional neural circuits in neurodegenerative disease and brain injury. Its lead program targets Levodopa-Induced Dyskinesia, with planned expansion into Parkinson’s Disease and broader central nervous system indications. For more information, visit fivediscovery.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding Five Discovery’s research and development plans, regulatory strategy, and potential therapeutic applications. These statements are subject to risks and uncertainties that may cause actual results to differ materially.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260224982333/en/